JP6903571B2 - スミス‐マゲニス症候群を治療するためのタシメルテオン - Google Patents

スミス‐マゲニス症候群を治療するためのタシメルテオン Download PDF

Info

Publication number
JP6903571B2
JP6903571B2 JP2017512287A JP2017512287A JP6903571B2 JP 6903571 B2 JP6903571 B2 JP 6903571B2 JP 2017512287 A JP2017512287 A JP 2017512287A JP 2017512287 A JP2017512287 A JP 2017512287A JP 6903571 B2 JP6903571 B2 JP 6903571B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sleep
composition according
melatonin
tasimelteon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017512287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526693A5 (OSRAM
JP2017526693A (ja
Inventor
クリスティン ラヴダン、
クリスティン ラヴダン、
マイケル、 エイチ． ポリメロポロス、
マイケル、 エイチ． ポリメロポロス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6903571(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2017526693A publication Critical patent/JP2017526693A/ja
Publication of JP2017526693A5 publication Critical patent/JP2017526693A5/ja
Application granted granted Critical
Publication of JP6903571B2 publication Critical patent/JP6903571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Led Device Packages (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coils Or Transformers For Communication (AREA)
JP2017512287A 2014-09-02 2015-08-29 スミス‐マゲニス症候群を治療するためのタシメルテオン Active JP6903571B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020097599A Division JP7132277B2 (ja) 2014-09-02 2020-06-04 スミス‐マゲニス症候群を治療するためのタシメルテオン

Publications (3)

Publication Number Publication Date
JP2017526693A JP2017526693A (ja) 2017-09-14
JP2017526693A5 JP2017526693A5 (OSRAM) 2018-10-11
JP6903571B2 true JP6903571B2 (ja) 2021-07-14

Family

ID=54147267

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512287A Active JP6903571B2 (ja) 2014-09-02 2015-08-29 スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2020097599A Active JP7132277B2 (ja) 2014-09-02 2020-06-04 スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2022039475A Active JP7252390B2 (ja) 2014-09-02 2022-03-14 スミス‐マゲニス症候群を治療するためのタシメルテオン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020097599A Active JP7132277B2 (ja) 2014-09-02 2020-06-04 スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2022039475A Active JP7252390B2 (ja) 2014-09-02 2022-03-14 スミス‐マゲニス症候群を治療するためのタシメルテオン

Country Status (17)

Country Link
US (5) US10179119B2 (OSRAM)
EP (2) EP3188727B1 (OSRAM)
JP (3) JP6903571B2 (OSRAM)
KR (2) KR20170048541A (OSRAM)
CN (2) CN116098887A (OSRAM)
AU (2) AU2015312252B2 (OSRAM)
BR (1) BR112017003644A2 (OSRAM)
CA (2) CA2957588C (OSRAM)
DK (1) DK3188727T3 (OSRAM)
ES (1) ES2936833T3 (OSRAM)
FI (1) FI3188727T3 (OSRAM)
HR (1) HRP20230070T1 (OSRAM)
HU (1) HUE061051T2 (OSRAM)
MX (1) MX386150B (OSRAM)
PT (1) PT3188727T (OSRAM)
SI (1) SI3188727T1 (OSRAM)
WO (1) WO2016036619A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143159A (ja) * 2014-09-02 2020-09-10 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スミス‐マゲニス症候群を治療するためのタシメルテオン

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014841A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de agonista de melatonina.
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
MX2022006577A (es) * 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.
TWI891877B (zh) 2020-08-27 2025-08-01 日商友華股份有限公司 檢查裝置
CA3229930A1 (en) * 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
MX2008014841A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de agonista de melatonina.
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP4502609A3 (en) * 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
HRP20230070T1 (hr) * 2014-09-02 2023-03-17 Vanda Pharmaceuticals Inc. Tasimelteon za liječenje smith-magenis sindroma
MX2022006577A (es) * 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143159A (ja) * 2014-09-02 2020-09-10 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スミス‐マゲニス症候群を治療するためのタシメルテオン
JP7132277B2 (ja) 2014-09-02 2022-09-06 バンダ・ファーマシューティカルズ・インコーポレイテッド スミス‐マゲニス症候群を治療するためのタシメルテオン

Also Published As

Publication number Publication date
EP3188727A1 (en) 2017-07-12
AU2020239640A1 (en) 2020-10-15
AU2015312252A1 (en) 2017-03-30
CA2957588C (en) 2021-08-31
MX386150B (es) 2025-03-18
NZ765911A (en) 2023-08-25
PT3188727T (pt) 2023-01-30
NZ729901A (en) 2020-09-25
FI3188727T3 (fi) 2023-02-20
KR20240015729A (ko) 2024-02-05
CA2957588A1 (en) 2016-03-10
KR20170048541A (ko) 2017-05-08
EP3188727B1 (en) 2022-11-09
AU2020239640B2 (en) 2020-11-05
JP2020143159A (ja) 2020-09-10
CN116098887A (zh) 2023-05-12
HUE061051T2 (hu) 2023-05-28
JP7132277B2 (ja) 2022-09-06
EP4137129A1 (en) 2023-02-22
JP2022078291A (ja) 2022-05-24
DK3188727T3 (da) 2023-02-06
US20240293355A1 (en) 2024-09-05
SI3188727T1 (sl) 2023-03-31
US20190105297A1 (en) 2019-04-11
CA3124872A1 (en) 2016-03-10
US10653665B2 (en) 2020-05-19
US10179119B2 (en) 2019-01-15
HRP20230070T1 (hr) 2023-03-17
MX2017002796A (es) 2017-06-09
BR112017003644A2 (pt) 2017-11-28
US11266622B2 (en) 2022-03-08
JP7252390B2 (ja) 2023-04-04
WO2016036619A1 (en) 2016-03-10
AU2015312252B2 (en) 2020-07-02
US20170239210A1 (en) 2017-08-24
CN106604726A (zh) 2017-04-26
US20200237712A1 (en) 2020-07-30
JP2017526693A (ja) 2017-09-14
ES2936833T3 (es) 2023-03-22
US20220133681A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
JP7252390B2 (ja) スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2021130687A (ja) ガボキサドールでの発達障害の処置方法
EA015256B1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
JP2020534270A (ja) １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
TR201908928T4 (tr) Parkinsoniyan sendromları olan nörodejeneratif hastalıkları tedavi etmek için bümetanid.
CA3067929A1 (en) New uses of a pure 5-ht6 receptor antagonist
JP2019532046A (ja) 糖尿病に関連する神経障害の改善
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
EA042685B1 (ru) Новые применения чистого антагониста 5-ht6 рецептора

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200604

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200616

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200714

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210105

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210420

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210525

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210623

R150 Certificate of patent or registration of utility model

Ref document number: 6903571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250